MetaCap

Kazia Therapeutics (KZIA) vs Xilio Therapeutics (XLO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xilio Therapeutics (XLO) has outperformed Kazia Therapeutics (KZIA) over the past year, losing 28.3% versus a loss of 41.1%. Over five years, XLO leads with a -97.3% price change compared with -99.0% for KZIA. Kazia Therapeutics is the larger company by market cap ($56.2 million vs $53.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KZIA-41.08%XLO-28.29%
+110%+31%-48%
Nov 21, 20251 yearNov 20, 2026
KZIA-99.13%XLO-97.63%
+5%-50%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KZIA versus XLO key metrics
MetricKZIAXLO
Share price$4.92$7.56
Market cap$56.22M$53.40M
1-day change-8.38%-1.11%
YTD return-28.59%-15.63%
1-year return-41.08%-28.29%
5-year return-99.01%-97.29%
P/E ratio (TTM)—11.63
EPS (TTM)$-6.85$0.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$43.77M
Revenue growth (YoY)—+589.88%
Net income (latest FY)—$-35.04M
Operating margin—-95.92%
Net margin—-80.05%
52-week high$17.40$10.71
52-week low$4.50$6.47
Distance from 52-week high-71.72%-29.41%
Analyst consensusnonenone
Avg. price target upside+476.02%+164.55%
Average volume307.30K11.54K
Shares outstanding11.43M7.06M
Employees676
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XLO has outperformed KZIA by 12.8 percentage points over the past year.

About Kazia Therapeutics

KZIA stock →

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Xilio Therapeutics

XLO stock →

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

KZIA vs XLO FAQ

Which is bigger, Kazia Therapeutics or Xilio Therapeutics?

Kazia Therapeutics (KZIA) is larger, with a market capitalization of $56.22M compared with $53.40M for Xilio Therapeutics (XLO).

Which stock has performed better over the past year, KZIA or XLO?

XLO returned -28.29% over the past 12 months, compared with -41.08% for KZIA (price return, excluding dividends). Past performance does not predict future results.

Are Kazia Therapeutics and Xilio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons